Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AcuCort receives a second US patent protection for its drug ISICORT®

AcuCort AB (Spotlight Stock Market: ACUC) today announces that the US Patent and Trademark Office, USPTO, has announced that the company’s patent application in the US for dexamethasone oral film is granted. This is the second patent protection in the US for AcuCort’s drug ISICORT®. This strengthened patent protection and extended exclusivity on the US market is in line with company’s strategy.ISICORT® is a thin, fast-dissolving and user-friendly oral film for the treatment of acute and severe allergic reactions, for croup in children and chemotherapy-induced nausea and vomiting (CINV). The

Cell Impact strengthens management with new CHRO

Cell Impact AB (Nasdaq First North GM: Cell Impact AB (Nasdaq First North GM: CI B) is pleased to announce that Karina Sick Larsson has been appointed as Chief Human Resources Officer (CHRO) and will start her position on September 16, 2021. Karina will be responsible for the company's human resources function with a focus on organizational development.Karina has a solid and extensive background in HR that includes management positions at companies such as Cambrex and most recently at CAB Group. During this time, Karina has contributed substantially to growing and internationalizing

Artist and songwriter Elias Ringquist has released a new single with mental health as its central theme

The feel of the song is likened to “soundtrack music” and highlights the issues of depression and mental illness, while engaging the listener to look at challenges and setbacks in a more positive way. It is also about manifesting dreams and visions.– I wrote the song during anxiety and while feeling depressed, probably because I needed something to look up to. Going through grief, sadness or loneliness I think it's important to try to make something creative or positive out of it, that can give yourself new energy and strength. Be creative and give instead of not doing it, Elias Ringquist

Anora reschedules publication of the Q3 2021 report and announces financial calendar for 2022

Anora Group Plc   Stock Exchange Release   3 September 2022 at 5.20 pm EET Anora reschedules publication of the Q3 2021 report and announces financial calendar for 2022 Anora reschedules the publication of its Q3 2021 financial report to Thursday 25 November 2021. The previous publication date was 3 November 2021. Anora will publish the financial statements bulletin, half-year report and two business reviews in 2022 as follows: 10 March 2022: Financial Statements Bulletin for 2021 19 May 2022: Business Review for January-March 2022 1 September 2022: Half-Year Report for

Anora Group Plc: Employee representation on Anora’s Board of Directors and organisational meeting of the Board of Directors

Anora Group Plc    Stock Exchange Release   3 September 2021 at 5.15 pm EEST Anora Group Plc: Employee representation on Anora’s Board of Directors and organisational meeting of the Board of Directors Anora complies with the rules for arranging employee representation on the Board of Directors. As announced on 10 May 2021, Anora’s employees have the right to elect two employee representatives to Anora’s Board of Directors and the first employee representative has been elected. Anora’s employees have elected Arne Larsen as member of the Board of Directors. The term of office for the

American Shipping Company ASA : Primary insider disclosure

3 September 2021 - Peter D. Knudsen, board member of American Shipping Company ASA ("AMSC" or the "Company"), and members of his close family have today acquired 2,000 shares in AMSC through the company Vilja AS. The price per share was NOK 29.80, which implies a total consideration of NOK 59,600. Following the transaction, Vilja AS holds a total of 5,000 shares in AMSC, constituting approximately 0.008% of the Company's shares and votes. *** The information contained herein is subject to the disclosure requirements of section 4-2 of the Norwegian Securities Trading Act.

Mandatory notification of trade by Primary Insiders

Pexip Holding ASA ("Pexip" or "The Company", Oslo Børs Ticker: PEXIP) has been notified that Åsmund Fodland, President Global Sales & APAC has today, September 3, 2021, through Metrix Invest AS, controlled by Mr. Fodstad, bought 14,000 shares at NOK 71.57 per share. After the transaction, Mr. Fodstad and Metrix Invest AS will hold 740,525 shares and rights to 60,000 shares. The information included in this announcement is such that the Company is required to disclose in accordance with the EU Market Abuse Regulation (MAR) and is publicly disclosed in accordance with MAR and section 5-12

Successful placement of new senior unsecured bond issue

Axactor SE, rated B1/B by Moody’s/S&P (Positive/Stable), has successfully completed a new 5 year senior unsecured bond issue of EUR 300 million. The bond will be rated B3/B by Moody’s/S&P and carry a coupon of 3m EURIBOR + 5.35%. The net proceeds from the bond issue will be employed towards repaying existing debt facilities and general corporate purposes. An application will be made for listing on Oslo Stock Exchange. Arctic Securities, DNB Markets and Nordea acted as Joint Lead Managers in connection with the placement of the bond issue. For additional information, please contact:

Scandinavian ChemoTech's subsidiary Vetiqure AB begins its marketing in the US

As part of the feasibility study underway in the US ahead of the launch of the company's unique TSE (Tumour Specific Electroporation) technology, intended for the treatment of pets affected by cancer, Vetiqure AB plans to participate in a number of Veterinary Conferences during the autumn.The feasibility study, which started during the summer and will lead to a successful launch strategy in the USA, will enter a new phase during the autumn, where vetIQure™ will be shown to a larger group of veterinarians for the first time. Through its presence, the company wishes to introduce and

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT AUGUST 2021

Strong sales growth during August; Zinzino group revenue increased with a total of 14%, compared with the previous year.The revenue in August for Zinzino's sales markets increased by 13% to SEK 92.2 (81.9) million due to strong growth in several regions. Faun Pharma's external sales increased by 37% and amounted to SEK 4.8 (3.5) million. Overall, the Group increased revenues by 14% to SEK 97.0 (85.4) million compared with the previous year. Accumulated revenue for January – August 2021 increased by 23% to SEK 851.3 (690.9) million. Revenues were distributed as follows: Regions,MSEK

Investment AB Latour (publ) issues bond loan

Today Investment AB Latour (publ) “Latour” issued a bond loan of in total SEK 1,000 m, within the aggregate nominal amount of the existing MTN program. The bond loan was issued with a tenor of 5.75 years and matures on 16 June, 2027, and carries a floating interest rate of three months STIBOR + a margin of 0.57 per cent annually. The issuance is an extension of the existing loan 112 and the total volume of the loan after the issuance amounts to SEK 1,400 m. Handelsbanken and SEB have arranged the issuance. Immediately after the issue, Latour entered a swap contract which means that

Board member of Immunovia purchases shares in the company

LUND, SWEDEN - Immunovia AB (publ) (“Immunovia”) announces today that board member Martin Møller purchases 1,056 shares in Immunovia, an investment of a total of SEK 141,295. This is Martin Møller's total holding after the purchase. For more information, please contact:Patrik Dahlen, CEO ImmunoviaEmail: patrik.dahlen@immunovia.comTel: +46 73 376 76 64 About ImmunoviaImmunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform

BioStock: Targinta’s new CEO has started

On September 1, Per Norlén took on the role of CEO of Targinta, Xintela's oncology subsidiary, which is being prepared to be spun off from Xintela in 2021. Norlén plans to develop Targinta to become an independent and self-funded cancer company, which he talks more about in an interview with BioStock.Read the full interview with Targinta's CEO Per Norlén at biostock.se: https://www.biostock.se/en/2021/09/targintas-new-ceo-has-started/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Viessmann Refrigeration Solutions takes over Fri-Service and expands market presence in the Czech Republic and Slovakia

Viessmann Refrigeration Solutions takes over Fri-Service, a well-established refrigeration solutions provider in the Czech Republic and Slovakia.Mainz, Germany, September 3rd 2021 - Viessmann Refrigeration Solutions takes over Fri-Service, a well-established refrigeration solutions provider in the Czech Republic and Slovakia. Next to the existing service companies, the acquisition strengthens Viessmann’s own service and turnkey solutions capabilities for customers, who will have full support from the planning stage through to implementation and maintenance of the projects from Viessmann.

Shareholders' Nomination Board appointed at Detection Technology

Detection Technology Plc company announcement 3 September 2021 at 15:00 (EEST) Shareholders' Nomination Board appointed at Detection Technology A Shareholders' Nomination Board has been appointed at Detection Technology according to holdings on 1 September 2021. CEO of Ahlström Capital Lasse Heinonen has been appointed Chairman of the Nomination Board as the representative of Ahlstrom Capital BV, and Board Member of OP Fund Management Company Kalle Saariaho representing the OP mutual funds and, Director, Sustainability of Aktia Bank Markus Lindqvist representing the Aktia Capital have

DNB Markets: Episurf Medical - New long-term data strengthens the story

The company announced on 2 September that the 5–7-year follow-up data for the first trial with the Episealer system has been accepted for publication. We view this as important (even though it is a small trial) as it should validate the long-term outcome of Episealer treatment. We understand there have been no revisions for five years and the patients feel as well as after the 2-year follow-up. We reiterate our fair value of SEK2.7–8.2.Long-term follow-up data of first Episealer patients to be published. The company announced on 2 September that the long-term follow-up data for the first

Lagercrantz welcomes Peter Thysell as new CFO

Lagercrantz Group will appoint Peter Thysell as new CFO, tentatively from 1 December 2021. Peter has extensive experience from unlisted, risk capital-owned and listed companies and joins the Group from RaySearch Laboratories AB (publ) where he most recently held the position of CFO.“I am very happy to welcome Peter to the role of CFO at Lagercrantz Group. His business breadth, experience, ambition and profile will be an asset in the journey towards the next phase in the Group's development,” says Jörgen Wigh, President and CEO of Lagercrantz Group. Peter Thysell grew up in Kalmar and

Anora Group Plc: Managers' transactions - Canica AS

Anora Group Plc       Managers' Transactions    3 September 2021 at 2:30 pm EET   Anora Group Plc - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Canica ASPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Nils SeltePosition: Member of the Board Issuer: Anora Group PlcLEI: 52990007AXNSS4PNX352 Notification type: INITIAL NOTIFICATIONReference number: 52990007AXNSS4PNX352_20210903125723_6_________________________________

Anora Group Plc: Managers' transactions - Michael Holm Johansen

Anora Group Plc       Managers' Transactions    3 September 2021 at 2:30 pm EET   Anora Group Plc - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Johansen Michael HolmPosition: Member of the Board/Deputy memberIssuer: Anora Group PlcLEI: 52990007AXNSS4PNX352 Notification type: INITIAL NOTIFICATIONReference number: 52990007AXNSS4PNX352_20210903125706_10____________________________________________ Transaction date: 2021-09-01Venue not applicableInstrument type: SHAREISIN: FI4000292438

Anora Group Plc: Managers' transactions - Sigmund Toth

Anora Group Plc       Managers' Transactions    3 September 2021 at 2:30 pm EET   Anora Group Plc - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Toth SigmundPosition: Chief Financial Officer(X) Legal personIssuer: Anora Group PlcLEI: 52990007AXNSS4PNX352 Notification type: INITIAL NOTIFICATIONReference number: 52990007AXNSS4PNX352_20210903125754_8____________________________________________ Transaction date: 2021-09-01Venue not applicableInstrument type: SHAREISIN: FI4000292438

Anora Group Plc: Managers' transactions - Hoff AS

Anora Group Plc       Managers' Transactions    3 September 2021 at 2:30 pm EET   Anora Group Plc - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Hoff SAPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Flønes IngeborgPosition: Member of the Board Issuer: Anora Group PlcLEI: 52990007AXNSS4PNX352 Notification type: INITIAL NOTIFICATIONReference number: 52990007AXNSS4PNX352_20210903125740_7______________________________

Crunchfish exits Food Waste business

Crunchfish’s business area Food Waste was based on a granted Swedish patent. The patent has been challenged and after careful analysis, Crunchfish has concluded that the patent will not stand and that a potentially modified patent will not be sufficient to build the business. Crunchfish has therefore decided to exit its operations in the Food Waste segment.Crunchfish is increasingly focusing on Digital Cash and with the conclusion that the granted patent within food waste will not stand and that a potentially modified patent will not be sufficiently broad to build a viable business,

Nature Medicine publishes phase 3 anakinra study results in patients with COVID-19 pneumonia

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and the Hellenic Institute for the Study of Sepsis today announce that Nature Medicine has published positive results from the investigator-sponsored phase 3 SAVE-MORE study evaluating anakinra plus standard of care (SOC) in patients with moderate-to-severe COVID-19 pneumonia. The study demonstrated that early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases likelihood of full recovery in hospitalised COVID-19 patients with poor prognosis due to risk of severe

There are no items matching the current filter
There are no more items matching the current filter
Back to top